162 related articles for article (PubMed ID: 10585454)
1. How an inhibitor of the HIV-I protease modulates proteasome activity.
Schmidtke G; Holzhütter HG; Bogyo M; Kairies N; Groll M; de Giuli R; Emch S; Groettrup M
J Biol Chem; 1999 Dec; 274(50):35734-40. PubMed ID: 10585454
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
André P; Groettrup M; Klenerman P; de Giuli R; Booth BL; Cerundolo V; Bonneville M; Jotereau F; Zinkernagel RM; Lotteau V
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13120-4. PubMed ID: 9789051
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.
Gaedicke S; Firat-Geier E; Constantiniu O; Lucchiari-Hartz M; Freudenberg M; Galanos C; Niedermann G
Cancer Res; 2002 Dec; 62(23):6901-8. PubMed ID: 12460905
[TBL] [Abstract][Full Text] [Related]
4. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome.
Schmidtke G; Emch S; Groettrup M; Holzhutter HG
J Biol Chem; 2000 Jul; 275(29):22056-63. PubMed ID: 10806206
[TBL] [Abstract][Full Text] [Related]
5. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.
Meng L; Mohan R; Kwok BH; Elofsson M; Sin N; Crews CM
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10403-8. PubMed ID: 10468620
[TBL] [Abstract][Full Text] [Related]
6. Glutathiolation of the proteasome is enhanced by proteolytic inhibitors.
Demasi M; Shringarpure R; Davies KJ
Arch Biochem Biophys; 2001 May; 389(2):254-63. PubMed ID: 11339815
[TBL] [Abstract][Full Text] [Related]
7. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.
Schubert U; Antón LC; Bacík I; Cox JH; Bour S; Bennink JR; Orlowski M; Strebel K; Yewdell JW
J Virol; 1998 Mar; 72(3):2280-8. PubMed ID: 9499087
[TBL] [Abstract][Full Text] [Related]
8. Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Hosseini H; André P; Lefevre N; Viala L; Walzer T; Peschanski M; Lotteau V
J Neuroimmunol; 2001 Aug; 118(2):233-44. PubMed ID: 11498258
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.
Groll M; Koguchi Y; Huber R; Kohno J
J Mol Biol; 2001 Aug; 311(3):543-8. PubMed ID: 11493007
[TBL] [Abstract][Full Text] [Related]
10. Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome.
Mellgren RL
J Biol Chem; 1997 Nov; 272(47):29899-903. PubMed ID: 9368065
[TBL] [Abstract][Full Text] [Related]
11. Proteolysis. The proteasome: a protein-degrading organelle?
Rubin DM; Finley D
Curr Biol; 1995 Aug; 5(8):854-8. PubMed ID: 7583140
[TBL] [Abstract][Full Text] [Related]
12. Opening doors into the proteasome.
Pickart CM; VanDemark AP
Nat Struct Biol; 2000 Nov; 7(11):999-1001. PubMed ID: 11062549
[No Abstract] [Full Text] [Related]
13. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing.
Heinemeyer W; Fischer M; Krimmer T; Stachon U; Wolf DH
J Biol Chem; 1997 Oct; 272(40):25200-9. PubMed ID: 9312134
[TBL] [Abstract][Full Text] [Related]
14. A proteolytic system that compensates for loss of proteasome function.
Glas R; Bogyo M; McMaster JS; Gaczynska M; Ploegh HL
Nature; 1998 Apr; 392(6676):618-22. PubMed ID: 9560160
[TBL] [Abstract][Full Text] [Related]
15. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
Schwarz K; de Giuli R; Schmidtke G; Kostka S; van den Broek M; Kim KB; Crews CM; Kraft R; Groettrup M
J Immunol; 2000 Jun; 164(12):6147-57. PubMed ID: 10843664
[TBL] [Abstract][Full Text] [Related]
16. Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.
Princiotta MF; Schubert U; Chen W; Bennink JR; Myung J; Crews CM; Yewdell JW
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):513-8. PubMed ID: 11149939
[TBL] [Abstract][Full Text] [Related]
17. Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome.
Elsasser S; Chandler-Militello D; Müller B; Hanna J; Finley D
J Biol Chem; 2004 Jun; 279(26):26817-22. PubMed ID: 15117949
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors and antigen presentation.
Bogyo M; Gaczynska M; Ploegh HL
Biopolymers; 1997; 43(4):269-80. PubMed ID: 9316392
[TBL] [Abstract][Full Text] [Related]
19. Studies on the yeast proteasome uncover its basic structural features and multiple in vivo functions.
Hilt W; Heinemeyer W; Wolf DH
Enzyme Protein; 1993; 47(4-6):189-201. PubMed ID: 7697119
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex.
Zhang Z; Torii N; Furusaka A; Malayaman N; Hu Z; Liang TJ
J Biol Chem; 2000 May; 275(20):15157-65. PubMed ID: 10748218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
